EchoGo Amyloidosis vs VX1
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 60/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
These tools are adjacent rather than direct competitors, as they serve distinct purposes within cardiology. EchoGo Amyloidosis focuses on the early detection of cardiac amyloidosis through echocardiogram analysis, aiding in diagnosis and screening. In contrast, VX1 is designed to assist cardiac electrophysiologists in real-time during atrial fibrillation and atrial tachycardia ablation procedures by identifying dispersed electrograms.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
EchoGo Amyloidosis is an FDA-cleared AI-powered screening tool designed to aid in the early detection of cardiac amyloidosis (CA) by analyzing echocardiogram video clips. VX1 is an FDA-cleared AI software that assists cardiac electrophysiologists in real-time identification of dispersed electrograms during atrial fibrillation and atrial tachycardia ablation procedures.
EchoGo Amyloidosis is a cloud-based SaaS model that offers seamless integration with existing clinical workflows and IT infrastructure, including PACS, DICOM, and HL7. VX1 is software integrated with existing electrophysiology (EP) lab mapping and recording systems, and it is compatible with most EP recording, 3D navigation systems, and mapping catheters.
EchoGo Amyloidosis boasts high diagnostic accuracy for cardiac amyloidosis, with 85% sensitivity and 93% specificity, and consistent performance across CA subtypes. VX1 is designed to reduce inter-operator variability and standardize outcomes during AFib and atrial tachycardia ablation procedures by providing AI-guided real-time identification of dispersed electrograms.
For EchoGo Amyloidosis, there are specific reimbursement pathways: Inpatient use is covered by NTAP Code ICD-10 XXE2X19 at $1,000 per analysis (Medicare-covered), and Outpatient use is covered by HCPCS Code C9786, Clinical APC Code 574 at $285 per analysis (covered by Medicare and select commercial insurers). VX1's pricing is available upon contact, and specific reimbursement codes are not explicitly stated in the provided information.
EchoGo Amyloidosis analyzes echocardiogram video clips, focusing on echocardiographic markers such as ventricular volume, cardiac function, and myocardial movement. VX1 analyzes 3D anatomical and electrical maps of human atria and electrograms to identify dispersed electrograms and provide cycle length estimation.